Leiden Jeffrey M's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed May 9, 2023
- Accession no.
- 0001209191-23-028240
- Filed
- May 9, 2023
- Trade date
- May 5-8, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $699.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leiden Jeffrey MCIK 0001242825 | Director, Officer (Executive Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 5, 2023 | Common Stock | SSaleDisposed | −708 | $349.38F2,F3 | −$247,361.04 | 36,683 | Direct | |
| May 5, 2023 | Common Stock | SSaleDisposed | −171 | $350.30F2,F4 | −$59,901.3 | 36,512 | Direct | |
| May 8, 2023 | Common Stock | SSaleDisposed | −1,125 | $349.00 | −$392,625 | 35,387 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 2 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $349.38 (range $349.00 to $349.95).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $350.30 (range $350.12 to $350.40).
Referenced by the price of 1 transaction in Table I.